This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakashima, H Articles by Yamamoto, N Search for Related Content PubMed PubMed Citation Articles by Nakashima, H Articles by Yamamoto, N

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1986 December; 30(6): 933-937

Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.

H Nakashima, T Matsui, S Harada, N Kobayashi, A Matsuda, T Ueda and N Yamamoto

ABSTRACT

Human T cell lymphotropic virus type III (HTLV-III)/lymphadenopathy-associated virus is the etiologic agent of the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. The effect of 3'-azido-3'-deoxythymidine (AZT) on the HTLV-III/lymphadenopathy-associated virus infection was quantitatively studied with HTLV type I-carrying MT-4 cells. The AZT compound inhibited HTLV-III-induced cytopathic effect and virus-specific antigen expression in MT-4 cells at concentrations of 5 and 10 microM. In addition, a plaque-forming assay was performed to assess the effect of AZT on virus replication in MT-4 cells freshly infected with HTLV-III and in continuous HTLV-III-producing Molt-4/HTLV-III cells. Results showed that AZT efficiently and effectively inhibited the replication of HTLV-III in infected MT-4 cells. AZT is a strong inhibitor of reverse transcriptase activity of HTLV-III as a triphosphate, to such a degree that even 1.0 pM azido-TTP inhibits 50% of reverse transcriptase activity. However, it did not show any effect in the HTLV-III-producing cell line Molt-4/HTLV-III. Thus, AZT has no effect on virus replication of an already integrated virus. When 5 microM AZT was added to HTLV-III-infected MT-4 within 20 h after infection, a striking suppressive effect was noticed. This concentration was much lower than that which inhibits the growth of MT-4 cells. These results confirm those found in a previous report (H. Mitsuya, K. J. Weinhold, P. S. Furman, H. S. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder, Proc. Natl. Acad. Sci. USA 82:7096-7100, 1985) and suggest that AZT might be used as an experimental antiviral agent for AIDS and AIDS-related complex.

---

Antimicrob Agents Chemother. 1986 December; 30(6): 933-937

This article has been cited by other articles:

• Watson, K. M., Buckheit, C. E., Buckheit, R. W. Jr. (2008). Comparative Evaluation of Virus Transmission Inhibition by Dual-Acting Pyrimidinedione Microbicides Using the Microbicide Transmission and Sterilization Assay. Antimicrob. Agents Chemother. 52: 2787-2796 [Abstract] [Full Text]  
• Derse, D., Hill, S. A., Lloyd, P. A., Chung, H.-k., Morse, B. A. (2001). Examining Human T-Lymphotropic Virus Type 1 Infection and Replication by Cell-Free Infection with Recombinant Virus Vectors. J. Virol. 75: 8461-8468 [Abstract] [Full Text]  
• Packer, S. J., Cesario, T., Williams, J. H. Jr. (1988). Mycobacterium avium Complex Infection Presenting as Endobronchial Lesions in Immunosuppressed Patients. ANN INTERN MED 109: 389-393 [Abstract]